



# Supplementary Information

## **Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells**



Abderrahim El Guerrab, Mahchid Bamdad, Yves-Jean Bignon, Frédérique Penault-Llorca and Corinne Aubel

Full-length Western blots are shown in the same order as they appear in the main manuscript.



**CAL-51**



**HCC-1937**





**SUM-1315**





**Full-length blots – ERK and phospho-ERK – Figure 3**



**CAL-51**



**HCC-1937**





**SUM-1315**





**Full-length blots – AKT and phospho-AKT – Figure 3**



**CAL-51**



**HCC-1937**




**SUM-1315**




**Full-length blots – mTOR and phospho-mTOR – Figure 3**


**CAL-51**




p-P70S6K




**HCC-1937**




p-P70S6K



**SUM-1315**




p-P70S6K




**Full-length blots – P70S6K and phospho-P70S6K – Figure 3**


**CAL-51**




**HCC-1937**



**SUM-1315**




**phospho-4E-BP1**




**Full-length blots – 4E-BP1 and phospho-4E-BP1 – Figure 3**


**CAL-51**








**HCC-1937**



**SUM-1315**



**Full-length blots – Actin – Figure 3**



Full-length blots of Figure 5